In acute myeloid leukemia (AML) many patients experience relapse, despite the achievement of morphological complete remission; therefore, conventional morphologic criteria are currently considered inadequate for assessing the quality of the response after treatment. Quantification of measurable residual disease (MRD) has been established as a strong prognostic marker in AML and patients that test MRD negative have lower relapse rates and better survival than those who test positive. Different techniques, varying in their sensitivity and applicability to patients, are available for the measurement of MRD and their use as a guide for selecting the most optimal postremission therapy is an area of active investigation. Although still controversial, MRD prognostic value promises to support drug development serving as a surrogate biomarker, potentially useful for accelerating the regulatory approval of new agents. In this review, we will critically examine the methods used to detect MRD and its potential role as a study endpoint.

Meddi, E., Savi, A., Moretti, F., Mallegni, F., Palmieri, R., Paterno, G., et al. (2023). Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(4), 3062-3073 [10.3390/ijms24043062].

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML

Palmieri, Raffaele;Del Principe, Maria Ilaria;Buccisano, Francesco;Venditti, Adriano
;
2023-02-04

Abstract

In acute myeloid leukemia (AML) many patients experience relapse, despite the achievement of morphological complete remission; therefore, conventional morphologic criteria are currently considered inadequate for assessing the quality of the response after treatment. Quantification of measurable residual disease (MRD) has been established as a strong prognostic marker in AML and patients that test MRD negative have lower relapse rates and better survival than those who test positive. Different techniques, varying in their sensitivity and applicability to patients, are available for the measurement of MRD and their use as a guide for selecting the most optimal postremission therapy is an area of active investigation. Although still controversial, MRD prognostic value promises to support drug development serving as a surrogate biomarker, potentially useful for accelerating the regulatory approval of new agents. In this review, we will critically examine the methods used to detect MRD and its potential role as a study endpoint.
4-feb-2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Con Impact Factor ISI
https://doi.org/10.3390/ijms24043062
Meddi, E., Savi, A., Moretti, F., Mallegni, F., Palmieri, R., Paterno, G., et al. (2023). Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(4), 3062-3073 [10.3390/ijms24043062].
Meddi, E; Savi, A; Moretti, F; Mallegni, F; Palmieri, R; Paterno, G; Buzzatti, E; Del Principe, Mi; Buccisano, F; Venditti, A; Maurillo, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
ijms-24-03062.pdf

accesso aperto

Descrizione: Articolo
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 270.87 kB
Formato Adobe PDF
270.87 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/314217
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 8
social impact